Positive pre-clinical study data of Lamellar Biomedical's Visco-ease published in Supportive Care Journal

Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical devices and pharmaceuticals, based on Lamellasome™ technology, is pleased to announce the publication of a paper in the Supportive Care in Cancer Journal. The paper outlines the data from a positive pre-clinical study with Visco-ease (LMS-611) showing its ability to modify the properties of saliva of patients undergoing radiotherapy for Head & Neck Cancer.

The lead author of the paper titled ‘Radiotherapy-Induced Xerostomia, pre-clinical promise of LMS-611’ is Dr Claire Paterson, of the Beatson West of Scotland Cancer Centre.

Radiotherapy-Induced Xerostomia (RIX) is the most common permanent side effect of radiotherapy to the head and neck affecting patients’ ability to eat and swallow. Visco-ease (LMS-611) is a mimetic of a natural lamellar body which prevents thick secretions like saliva from congesting organs.

The primary objective of this pre-clinical study was to assess the properties of the saliva of patients before and during radiotherapy to treat their head and neck cancer. The secondary objectives were to assess saliva properties after the addition of LMS-611, measure inter-patient variability and correlate patient-reported symptoms with laboratory measurements. A total of thirty patients were enrolled in the study.

Dr Alec McLean, CEO of Lamellar, commented:

The publication of this pre-clinical study with Visco-ease, which was undertaken at the Beatson West of Scotland Cancer Centre, clearly demonstrates the potential of this novel medical device to radically improve the lives of patients suffering from RIX by restoring the functionality of their saliva. We will be conducting a clinical trial in conjunction with the Beatson which will start later this month.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Breaking through new research barriers with iPSC technology